Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:GSK NYSE:RDY On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGSKGSK$51.16+1.0%$53.38$35.45▼$61.69$103.81B0.364.85 million shs6.11 million shsRDYDr. Reddy's Laboratories$13.36+1.0%$13.36$12.19▼$16.17$11.15B0.272.22 million shs1.68 million shsThe 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGSKGSK-1.72%+2.93%+0.59%-8.37%+22.95%RDYDr. Reddy's Laboratories-0.30%-0.30%-0.19%-8.70%-14.90%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGSKGSK$51.16+1.0%$53.38$35.45▼$61.69$103.81B0.364.85 million shs6.11 million shsRDYDr. Reddy's Laboratories$13.36+1.0%$13.36$12.19▼$16.17$11.15B0.272.22 million shs1.68 million shsThe 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGSKGSK-1.72%+2.93%+0.59%-8.37%+22.95%RDYDr. Reddy's Laboratories-0.30%-0.30%-0.19%-8.70%-14.90%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGSKGSK 1.89Reduce$53.003.45% UpsideRDYDr. Reddy's Laboratories 1.67ReduceN/AN/ACurrent Analyst Ratings BreakdownLatest GSK and RDY Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/29/2026RDYDr. Reddy's Laboratories Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold (C) ➝ Hold (C+)5/12/2026RDYDr. Reddy's Laboratories Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C+) ➝ Hold (C)5/1/2026GSKGSK Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold (C+) ➝ Buy (B)4/27/2026RDYDr. Reddy's Laboratories Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold (C) ➝ Hold (C+)4/23/2026RDYDr. Reddy's Laboratories The Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeNeutral ➝ Sell3/19/2026GSKGSK Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy (B-) ➝ Hold (C+)(Data available from 6/9/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGSKGSK$43.07B2.41$5.97 per share8.58$10.32 per share4.96RDYDr. Reddy's Laboratories$335.93B0.03$0.85 per share15.63$4.86 per share2.74Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGSKGSK$7.54B$3.8513.3210.012.6417.82%44.28%11.49%7/28/2026 (Estimated)RDYDr. Reddy's Laboratories$456M$0.5822.9921.511.8812.90%12.34%8.24%7/22/2026 (Estimated)Latest GSK and RDY EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2026Q4 25/26RDYDr. Reddy's Laboratories$0.09$0.06-$0.03-$0.03$886.58 million$852.55 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthGSKGSK$1.813.53%-7.86%47.01%N/ARDYDr. Reddy's Laboratories$0.060.45%+6.96%10.34%N/ALatest GSK and RDY DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date4/29/2026GSKGSKquarterly$0.443.71%5/15/20265/15/20267/9/20261/1/2100GSKGSKquarterly$0.42064.3%8/15/20258/15/202510/9/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGSKGSK0.800.790.52RDYDr. Reddy's Laboratories0.031.801.34Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGSKGSK15.74%RDYDr. Reddy's Laboratories3.85%Insider OwnershipCompanyInsider OwnershipGSKGSK10.00%RDYDr. Reddy's Laboratories2.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableGSKGSK66,8412.03 billion1.83 billionOptionableRDYDr. Reddy's Laboratories27,527834.65 million817.96 millionOptionableGSK and RDY HeadlinesRecent News About These CompaniesNYSE Content Update: Dell Technologies Reports 88% Revenue Increase YoYMay 29, 2026 | prnewswire.comDr. Reddy’s Launches First Generic Semaglutide Injection in Canada After Health Canada NodMay 17, 2026 | theglobeandmail.comDr. Reddy's launches generic semaglutide in Canada, expands GLP-1 pushMay 16, 2026 | msn.comDr. Reddy's Laboratories Launches its Generic Semaglutide Injection in CanadaMay 16, 2026 | businesswire.comDr. Reddy's Laboratories Q4 Earnings Call HighlightsMay 14, 2026 | marketbeat.comDr. Reddy's Q4 Earnings and Revenues Miss Estimates, Stock DownMay 13, 2026 | zacks.comDr. Reddy’s Laboratories Limited (NYSE:RDY) Q4 2026 Earnings Call TranscriptMay 13, 2026 | insidermonkey.comDr. Reddy's Laboratories Ltd (RDY) Releases Q4 2026 Earnings: Revenue and Profits Plunge, Margins CompressedMay 12, 2026 | quiverquant.comQDoctor Reddy’s: Fiscal Q4 Earnings SnapshotMay 12, 2026 | wtop.comWDr. Reddy's Laboratories Limited (RDY) Q4 2026 Earnings Call TranscriptMay 12, 2026 | seekingalpha.comIndian drugmaker Dr Reddy's posts quarterly profit slumpMay 12, 2026 | reuters.comAMPH vs. RDY: Which Stock Should Value Investors Buy Now?April 29, 2026 | zacks.comCanada Approves Dr. Reddy's Generic Version of Novo Nordisk's OzempicApril 29, 2026 | wsj.comDr. Reddy's Laboratories Announces Health Canada Approval for Generic Semaglutide Injection in CanadaApril 29, 2026 | businesswire.comDr. Reddy's Laboratories announces launch of India's first DCGI-approved Semaglutide injection 'Obeda®' for Type 2 DiabetesMarch 23, 2026 | equitybulls.comEZacks Industry Outlook Highlights Teva Pharmaceuticals, Sandoz and Dr. Reddy'sMarch 5, 2026 | finance.yahoo.com3 Generic Drug Stocks to Watch Despite Industry HeadwindsMarch 4, 2026 | zacks.comDr. Reddy’s biosimilar for Bristol’s Orencia undergoes FDA reviewFebruary 20, 2026 | seekingalpha.comDr. Reddy's Announces USFDA Acceptance to Review Its Biologics License Application (BLA) for Proposed Interchangeable Biosimilar, AbataceptFebruary 20, 2026 | businesswire.comDr. Reddy’s Schedules Mumbai Investor Meet for February 23, 2026February 14, 2026 | theglobeandmail.comDr Reddy's Laboratories Ltd (RDY) Q3 2026 Earnings Call Highlights: Navigating Growth Amidst ...January 25, 2026 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeGSK and RDY Company DescriptionsGSK NYSE:GSK$51.16 +0.52 (+1.02%) Closing price 03:59 PM EasternExtended Trading$51.23 +0.07 (+0.14%) As of 05:08 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.Dr. Reddy's Laboratories NYSE:RDY$13.36 +0.13 (+0.95%) Closing price 03:59 PM EasternExtended Trading$13.35 -0.01 (-0.04%) As of 04:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. The Others segment engages in developing therapies in the fields of oncology and inflammation; research and development of differentiated formulations; and provides digital healthcare and information technology enabled business support services. The company offers its products for various therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Corning Is Paving AI's Future With Glass The J.M. Smucker Company’s Dividend: Too Sweet to Ignore? Why's Amazon Suddenly Lagging the S&P 500, and Is It a Warning? Apple's Siri AI Was Finally Announced, So Why Is the Stock Tanking? From Crypto to AI: Insiders Are Trading These 3 Stocks The Case for Intel Over Pure-Play Quantum Firms Has Temu-Owner PDD's Story Changed After Double Miss? Campbell's Soup Stock: Deep Value and a 7% Dividend Yield Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
